platform technology is designed specifically to address the requirements of
point-of-care and critical-care settings, and to increase access to accurate
diagnosis of life-threatening diseases and monitoring of chronically ill patients.
is a patent-protected biosensor platform. It is a disposable, highly sensitive,
immunoassay for the detection and quantification of proteins/biomarkers at the
point-of-care. It provides accurate and quantitative results, in a matter of 15
minutes or less, on drop-size body fluid, such as blood, saliva, and urine.
brings complex and expensive in-vitro diagnostic tests out of the laboratory
into the point-of-care settings, including doctor’s offices, patient’s bedside,
homes, and low-resources settings. It provides accurate results that
compare for sensitivity and specificity to ELISA and other lab-based
immunoassays, while remaining low-cost, robust, easy to use, portable and
Unlike any other
point-of-care or laboratory-based immunoassays, pScreen™ does not
require electrical power, battery or supporting hand-held devices. Hence, pScreen™
is entirely disposable and low cost. This feature makes pScreen™
uniquely positioned to become the Point-of-Care diagnostic test of choice for
millions of people and healthcare practitioners.
The pScreen™ platform leverages the “micro-aggregation induced differential flow rate” (Mid-flow™) technology, developed at Carnegie Mellon University and under the support of a two-year NIH $400,000 grant. The Mid-flow™ is an elegantly simple yet effective detection technology, originally developed for detecting magnetic red blood cells. During the past two years of research, its versatility was significantly expanded to detect and quantify the concentration of protein and biomarkers.
Disclaimer: Accel Diagnostics makes no representation that materials at this Site are
appropriate or available for use in or outside the United States. The contents
of this site are copyrighted unless otherwise noted.